ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2970

Primary Care Assessment of Capillaroscopy Abnormalities in Patients with Raynaud’s Phenomenon

Rebecca Overbury1, Maureen Murtaugh2, Aryeh Fischer3 and Tracy M. Frech4, 1Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, 2Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, 3University of Colorado School of Medicine, Aurora, CO, 4Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: capillaroscopy and scleroderma, Raynaud's phenomenon

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Raynaud’s phenomenon is a clinical symptom that can commonly present to a primary care provider or generalist. Proper identification of an underlying connective tissue disease in a patient with Raynaud’s could allow for the prevention of possible critical digital ischemia.  Capillaroscopy is a tool which can identify abnormalities associated with connective tissue disease.

Methods: Patients presenting with a complaint of Raynaud’s phenomenon were assessed with capillaroscopy. In twenty consecutive Raynaud’s patients 8 digits were assessed by a 200X magnification dermatoscope and an image was obtained. Each image was assessed for the following abnormalities: drop-out (<9 capillaries in 1 mm); micro-hemorrhage; dilated loops; and neoangiogenesis.  These 160 images were then shown to 20 primary care physicians, who assessed these same abnormalities.  The interrater reliability, a measure of agreement, of individual primary care providers with the expert provider was assessed using kappa statistics.

Results: The total agreement from the 20 primary care providers was moderate (kappa =0.50, 95% CI: 0.49, 0.55). Three raters had slight agreement (in the range 0 to 0.20), one rater had fair agreement (0.21 to 0.40), 11 raters had moderate agreement (0.41 to 0.60), 5 raters had substantial agreement (0.61 to 0.80), and no rater had almost perfect agreement (0.81 to 1.00) For the four providers with slight to fair interrater reliabilities, the most common disagreement was providing a positive diagnosis when the expert rater diagnosed the digit negative. Ten of the 20 primary care providers provided at least one additional diagnosis following an abnormal diagnosis (n= 35 digits or 35% of the 1,556 abnormal ratings by the primary care providers). The four providers with the poorest interrater reliabilities were not among the 10 providers who participated in making these additional specific diagnoses. These providers achieved the moderate agreement with the expert provider for diagnoses of micro-hemorrhage (kappa = 0.64, 95% CI: 0.57, 0.70), but fair agreement with the expert provider for diagnoses of dilated loops (kappa = 0.27, 95% CI: 0.20, 0.34) and neoangiogenesis (kappa = 0.22, 95%CI: 0.13, 0.31).

Conclusion: Capillaroscopy is a potentially contributive clinical exam skill that could assist primary care providers and generalists in identifying and qualifying changes associated with the common presentation of Raynaud’s disease. However, formal training is needed to ensure accuracy and reproducibility. Furthermore, training and scoring systems should address time constraints of busy primary care practitioners.


Disclosure: R. Overbury, None; M. Murtaugh, None; A. Fischer, Genentech and Biogen IDEC Inc., 2,Actelion Pharmaceuticals US, 5,GlaxoSmithKline, 5,Boehringer Ingelheim, 1,Gilead Sciences, 5,Seattle Genetics, 5,Bristol-Myers Squibb, 5; T. M. Frech, None.

To cite this abstract in AMA style:

Overbury R, Murtaugh M, Fischer A, Frech TM. Primary Care Assessment of Capillaroscopy Abnormalities in Patients with Raynaud’s Phenomenon [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/primary-care-assessment-of-capillaroscopy-abnormalities-in-patients-with-raynauds-phenomenon/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/primary-care-assessment-of-capillaroscopy-abnormalities-in-patients-with-raynauds-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology